Health Reference Library

Do vitamin D deficiency and poor sleep compound immune risk?

Last reviewed 2 May 2026

This entry is part of the Nutri Tailor Health Reference Library — cited research on supplements, nutrients and adjacent areas of health.

Summary

Vitamin D and sleep have separate, partially-overlapping effects on immunity. Martineau 2017 (PMID 28202713, n=10,933) found vitamin D modestly protective against acute respiratory infection (OR 0.88), strongest in adults below 25(OH)D 25 nmol/L (OR 0.30); the effect attenuated in Jolliffe 2021 (PMID 33798465, n=75,541, OR 0.92). Sleep deprivation reduces NK activity, vaccine response, and elevates inflammatory cytokines (Cohen 2009, Prather 2015, Besedovsky 2012/2019). The compound benefit is mechanistically plausible but not directly trial-tested.

How it works

The compound claim that combined vitamin D deficiency and poor sleep creates an immune state worse than either alone is mechanistically plausible but has not been directly tested in RCTs. Sleep deprivation reduces NK cell activity, impairs antibody response to vaccination across multiple vaccine RCTs, elevates inflammatory cytokines (IL-6, TNF-alpha), and disrupts T-cell trafficking and immune memory consolidation per Besedovsky 2012 (Pflugers Arch 463:121-137, PMID 22071480) and Besedovsky 2019 (Physiol Rev 99:1325-1380, PMID 30920354) reviews.

Effective dose

Martineau 2017 IPDMA: 25 RCTs, n=10,933, overall OR 0.88 (95% CI 0.81-0.96) for acute respiratory infection, NNT 33; subgroup with 25(OH)D below 25 nmol/L OR 0.30 (0.17-0.53), NNT 4. Jolliffe 2021 (Lancet Diab Endocrinol, n=75,541, PMID 33798465) OR 0.92 (0.86-0.99); 2025 update OR 0.94 (0.88-1.00, p=0.057). Population-wide effect has attenuated as larger trial pools have been incorporated; strongest evidence remains for adults with documented deficiency.

Forms compared

Martineau 2017 found daily or weekly dosing more effective than bolus regimens; this favours standard daily supplementation over occasional large doses for immune-related rationale.

Timing

Within the autumn-winter window, consistent daily dosing aligns better with the Martineau 2017 evidence pattern than infrequent large doses. The relevant 25(OH)D target for respiratory-infection benefit is reaching above 25-50 nmol/L; standard NHS doses achieve this in most adults over 8-12 weeks (entry b9aee79e covers rate-of-rise expectations).

Safety profile

Persistent susceptibility to respiratory infection (more than 4-6 colds per year in adults; recurrent severe infections; chronic sinus or chest symptoms) warrants clinical assessment for underlying contributors including primary immunodeficiency, ENT pathology, asthma, smoking-related airways disease, and chronic conditions affecting immune function. Self-administered higher-dose protocols for immune support beyond NHS recommendations have weak evidence in non-deficient adults.

Special populations

Shift workers: sleep disruption is the dominant immune variable; vitamin D status is secondary. Transplant recipients, those on chemotherapy, advanced HIV, or primary immunodeficiency: vitamin D status assessment is reasonable but high-dose supplementation should be specialist-supervised because of immunomodulatory drug interactions and the underlying disease context.

Interactions

Some compound-immunity protocols add zinc 15-20 mg and vitamin C 500-1000 mg. Evidence position: zinc lozenges (not oral zinc tablets) shorten cold duration in some trials per Hemila Cochrane reviews; systemic immune effects of moderate zinc in non-deficient adults are smaller. Vitamin C does not reduce cold incidence in the general population (Hemila Cochrane) but reduces cold duration modestly (around 8% in adults, 14% in children) at doses 200 mg/day or higher. Both are best framed as separate interventions with their own modest evidence bases. Vitamin C upper intake level is 2,000 mg/day per IOM and EFSA.

Guideline positions

Martineau 2017 (BMJ 356:i6583, PMID 28202713) is the canonical IPDMA on vitamin D for acute respiratory infection. Jolliffe 2021 (Lancet Diab Endocrinol, PMID 33798465) is the largest update. Cohen 2009 (Arch Intern Med 169(1):62-67, PMID 19139325) and Prather 2015 (Sleep 38(9):1353-1359, PMID 26118561) anchor the sleep-immunity evidence. Besedovsky 2012 and 2019 are the canonical mechanistic reviews.

Practical framework

For UK adults practising the standard NHS supplementation framework with adequate sleep, no routine monitoring is required in asymptomatic individuals. Higher-dose supplementation for documented deficiency requires clinical assessment (entry 089dd947). Recurrent infections warrant clinical workup rather than escalating self-supplementation. This is a summary of published research, not personal health advice. Discuss any health or supplement decisions with a qualified healthcare professional, particularly during ongoing care, pregnancy, or with chronic conditions.

Common misconceptions

Claim: framing zinc lozenges and oral zinc tablets interchangeably (the lozenge evidence does not transfer); citing the 2017 Martineau effect size as if it remains current when 2021 and 2025 updates show attenuation; assuming higher daily doses (above 1,000 IU) confer additional immune benefit when this is not supported in non-deficient adults.

Who this matters for

This entry is relevant for the following groups, conditions, and medication contexts:

Sources

  1. Martineau AR, Jolliffe DA, Hooper RL, Greenberg L, Aloia JF, Bergman P, Dubnov-Raz G, Esposito S, Ganmaa D, Ginde AA, Goodall EC, Grant CC, Griffiths CJ, Janssens W, Laaksi I, Manaseki-Holland S, Mauger D, Murdoch DR, Neale R, Rees JR, Simpson S Jr, Stelmach I, Trilok Kumar G, Urashima M, Camargo CA Jr 2017. Vitamin D supplementation to prevent acute respiratory tract infections: systematic review and meta-analysis of individual participant data. BMJ. PMID: 28202713 · DOI: 10.1136/bmj.i6583
  2. Jolliffe DA, Camargo CA Jr, Sluyter JD, Aglipay M, Aloia JF, Ganmaa D, et al. 2021. Vitamin D supplementation to prevent acute respiratory infections: a systematic review and meta-analysis of aggregate data from randomised controlled trials. Lancet Diabetes & Endocrinology. PMID: 33798465 · DOI: 10.1016/s2213-8587(21)00051-6
  3. Jolliffe DA, Martineau AR, et al. 2025. Vitamin D supplementation to prevent acute respiratory infections: systematic review and meta-analysis of stratified aggregate data (2025 update). Lancet Diabetes & Endocrinology. PMID: 39993397 · DOI: 10.1016/s2213-8587(24)00348-6
  4. Cohen S, Doyle WJ, Alper CM, Janicki-Deverts D, Turner RB 2009. Sleep habits and susceptibility to the common cold. Archives of Internal Medicine. PMID: 19139325 · DOI: 10.1001/archinternmed.2008.505
  5. Prather AA, Janicki-Deverts D, Hall MH, Cohen S 2015. Behaviorally Assessed Sleep and Susceptibility to the Common Cold. Sleep. PMID: 26118561 · DOI: 10.5665/sleep.4968
  6. Besedovsky L, Lange T, Born J 2012. Sleep and immune function. Pflügers Archiv - European Journal of Physiology. PMID: 22071480 · DOI: 10.1007/s00424-011-1044-0
  7. Besedovsky L, Lange T, Haack M 2019. The Sleep-Immune Crosstalk in Health and Disease. Physiological Reviews. PMID: 30920354 · DOI: 10.1152/physrev.00010.2018
  8. Demay MB, Pittas AG, Bikle DD, Diab DL, Kiely ME, Lazaretti-Castro M, Lips P, Mitchell DM, Murad MH, Powers S, Rao SD, Scragg R, Tayek JA, Valent AM, Walsh JME, McCartney CR 2024. Vitamin D for the prevention of disease: an Endocrine Society clinical practice guideline. Journal of Clinical Endocrinology and Metabolism. PMID: 38828931 · DOI: 10.1210/clinem/dgae290
  9. NHS UK. Vitamin D. NHS UK (UK government).

Related entries

Back to Vitamin D overview